9 Reasons Hypermobile Ehlers-Danlos Syndrome and Perimenopause Create a Dangerous Combination
So many women with hEDS describe the same bewildering experience: they had found a fragile equilibrium — the right physio routine, the right braces, the right pacing — and then perimenopause quietly dismantled it. Joints that had been manageable for years started subluxing again, pain crept back, and no one in the consulting room connected the two. That gap between lived experience and available information is exactly why this page exists.
Learn more about Rose →Estrogen Has Been Actively Supporting Connective Tissue — and Now It's Declining
Estrogen receptors are found throughout connective tissue, including in ligaments, tendons, and joint capsules, where estrogen helps regulate collagen synthesis and tissue stiffness. In women with hEDS, whose collagen is already structurally abnormal, this hormonal scaffolding plays an outsize role in whatever joint stability they have managed to achieve. As estrogen levels become erratic and then fall during perimenopause, that scaffolding begins to shift — often in ways that feel sudden and unexplained to the woman experiencing it.
The Estrogen-Laxity Relationship Is Genuinely Complicated — and Disputed
Research on estrogen and connective tissue laxity produces apparently contradictory findings: some studies show estrogen increases ligament laxity (raising injury risk), while others show it supports collagen production and tissue integrity (protective). The truth is likely that estrogen's effect is tissue-specific, dose-dependent, and heavily modulated by individual receptor sensitivity — none of which has been studied in hEDS populations specifically. This means clinicians and patients are working from incomplete and sometimes conflicting evidence, which is important to acknowledge rather than paper over.
Perimenopausal Hormone Fluctuation May Be More Destabilising Than Consistent Low Estrogen
Perimenopause is not simply a gradual decline in estrogen — it is a period of dramatic, unpredictable swings where estrogen can spike to very high levels before dropping sharply, sometimes within the same cycle. For connective tissue that is already poorly regulated, these oscillations in hormonal environment may be more disruptive than the steadier low-estrogen state of established menopause. Women with hEDS often report that their worst period for joint instability is perimenopause itself rather than post-menopause, which is consistent with this fluctuation hypothesis.
Relaxin Sensitivity May Amplify Laxity Effects Beyond What Estrogen Alone Explains
Relaxin is a hormone that directly loosens ligaments and is partially modulated by estrogen signalling; there is emerging evidence that women with hEDS may have heightened sensitivity to relaxin, which could explain the exaggerated laxity some experience during pregnancy and hormonal transitions. If perimenopausal hormone shifts alter relaxin activity or receptor sensitivity, this could contribute to increased subluxation frequency in ways that standard connective tissue research does not capture. This area is significantly under-researched and represents one of the most important unanswered questions for this population.
Muscle Loss Begins in Perimenopause — and Muscle Is the Primary Stabiliser in hEDS
For women with hEDS, strong muscles are not a fitness goal but a medical necessity: because ligaments and joint capsules cannot be relied upon for stability, the surrounding musculature carries an abnormally high proportion of the load. Estrogen has a well-established protective effect on muscle mass and function, and its decline during perimenopause accelerates sarcopenia — the age-related loss of muscle tissue. When muscle loss coincides with potentially increased laxity, the protective buffer that most hEDS women have worked hard to build can erode relatively quickly.
Sleep Disruption Removes the Body's Primary Connective Tissue Repair Window
Collagen synthesis and tissue repair are heavily concentrated in deep sleep stages, and perimenopause is notorious for destroying sleep quality through night sweats, insomnia, and disrupted sleep architecture. For a woman with hEDS who is already working with structurally compromised connective tissue, losing the overnight repair window represents a meaningful additional burden on tissue integrity. Chronic sleep deprivation also raises systemic inflammation, which further degrades connective tissue quality over time.
The Proprioceptive Deficits of hEDS Worsen When Fatigue and Brain Fog Are Added
Proprioception — the body's ability to sense joint position in space — is measurably impaired in hEDS, contributing significantly to falls, missteps, and joint injuries. Perimenopausal brain fog, fatigue, and the neurological effects of estrogen withdrawal compound this deficit by slowing reaction times and reducing the processing speed needed to make real-time postural corrections. A body that already struggles to sense where its joints are becomes substantially more vulnerable to injury when cognitive and neurological function is also compromised.
Autonomic Dysfunction in hEDS Is Likely to Worsen With Estrogen Loss
A significant proportion of people with hEDS also have dysautonomia — dysfunction of the autonomic nervous system that can cause postural tachycardia (POTS), orthostatic intolerance, and cardiovascular instability on standing. Estrogen plays a regulatory role in autonomic nervous system tone, and its decline during perimenopause is associated with increased sympathetic nervous system activity and reduced cardiovascular autonomic control. For women already managing dysautonomia alongside hEDS, this hormonal shift can intensify symptoms that directly affect their ability to stay upright and physically active.
Most Clinicians — Including Specialists — Are Not Connecting These Two Conditions
Rheumatologists and physiotherapists managing hEDS are rarely trained in menopause medicine, while menopause specialists are rarely familiar with hEDS — meaning the woman in the middle routinely falls through the gap between two specialties that are not talking to each other. There is currently no clinical guidance specifically addressing the management of hEDS during perimenopause and menopause, which means women must often piece together information themselves and advocate explicitly for joined-up care. Understanding that this gap exists — and being able to name it in a clinical appointment — is itself a form of protection.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.